NICE released guidance on the use of tirzepatide for diabetes in October 2023.
What is tirzepatide?
Tirzepatide is an agonist at both the GLP-1 receptor (glucagon-like peptide 1) and the GIP receptor (glucose-dependent insulinotropic polypeptide). Stimulation of these receptors causes an increase in the release of GLP-1 and GIP and these in turn cause an increased release of insulin, a reduced glucagon release and delayed gastric emptying.
It both improves diabetes control and increases weight loss.
